

1 **How the COVID-19 pandemic affects transgender health care in upper-middle-income and**  
2 **high-income countries – A worldwide, cross-sectional survey**

3

4 **Short title: COVID-19 and transgender health care**

5

6 Andreas Koehler<sup>1</sup>, Joz Motmans<sup>2</sup>, Leo Mulió Alvarez<sup>3</sup>, David Azul<sup>4</sup>, Karen Badalyan<sup>5</sup>, Koray  
7 Basar<sup>6</sup>, Cecilia Dhejne<sup>7</sup>, Dragana Duišin<sup>8</sup>, Bartosz Grabski<sup>9</sup>, Aurore Dufrasne<sup>10</sup>, Natasa Jokic-  
8 Begic<sup>11</sup>, Antonio Prunas<sup>12</sup>, Christina Richards<sup>13</sup>, Kirill Sabir<sup>14</sup>, Jaimie Vaele<sup>15</sup>, Timo Ole  
9 Nieder<sup>1\*</sup>

10

11 <sup>1</sup> University Medical Center Hamburg-Eppendorf, Institute for Sex Research, Sexual  
12 Medicine, and Forensic Psychiatry, Martinistrasse 52, 20246 Hamburg, Germany

13

14 <sup>2</sup> Transgender Infopunt, Ghent University Hospital, Ghent, Belgium

15

16 <sup>3</sup> Transgender Europe, Berlin, Germany

17

18 <sup>4</sup> La Trobe University, La Trobe Rural Health School, Department of Community and Allied  
19 Health, Discipline of Speech Pathology, Melbourne, Australia

20

21 <sup>5</sup> Eurasian Key Populations Coalition, Warszawa, Poland

22

23 <sup>6</sup> Hacettepe University, Department of Psychiatry, Ankara, Turkey

24

25 <sup>7</sup> Karolinska University Hospital, Andrology, Sexual Medicine, Transgender Medicine,  
26 Stockholm, Sweden

27

28 <sup>8</sup> Clinical Centre of Serbia, Department of Psychiatry, Belgrade, Serbia

29

30 <sup>9</sup> Jagiellonian University Medical College, Sexology Lab, Department of Psychiatry, Krakow,  
31 Poland

32

33 <sup>10</sup> Genres Pluriels, Brussels, Belgium

34

35 <sup>11</sup> University of Zagreb, Clinical and Health Psychology Unit, Department of Psychology,  
36 Faculty of Humanities and Social Sciences, Zagreb, Croatia

37

38 <sup>12</sup> University of Milan, Department of Psychology, Milan, Italy

39

40 <sup>13</sup> Tavistock and Portman NHS Foundation Trust & Regents University London, School of  
41 Psychotherapy and Psychology, London, United Kingdom

42

43 <sup>14</sup> FtM Phoenix Group, Moscow, Russia

44

45 <sup>15</sup> University of Waikato, Faculty Arts & Social Sciences, New Zealand

46

47 \* [t.nieder@uke.de](mailto:t.nieder@uke.de)

48 **Abstract**

49 **Background**

50 Since the beginning of the COVID-19 pandemic, access to medical care was restricted for  
51 nearly all non-acute medical conditions. Due to their status as a vulnerable social group and  
52 the inherent need for transition-related treatments (e.g., hormone treatment), transgender  
53 people are assumed to be affected particularly severely by the restrictions caused by the  
54 COVID-19 pandemic. This study aims to assess the impact of the COVID-19 pandemic on the  
55 health and health care of transgender people.

56 **Methods and findings**

57 As an ad hoc collaboration between researchers, clinicians, and 23 community organizations,  
58 we developed a web-based survey. The survey was translated into 26 languages, and  
59 participants were recruited via various social media and LGBTIQ-community sources.  
60 Recruitment started in May 2020. We assessed demographical data, physical and mental  
61 health problems (e.g., chronic physical conditions), risk factors (e.g., smoking), COVID-19  
62 data (symptoms, contact history, knowledge and concerns about COVID-19), and the  
63 influence of the COVID-19 pandemic on access to transgender health care and health-related  
64 supplies. To identify factors associated with the experience of restrictions to transgender  
65 health care, we conducted multivariate logistic regression analysis.  
66 5267 transgender people from 63 higher-middle income and high-income countries  
67 participated in the study. Over 50% of the participants had risk factors for a severe course of  
68 a COVID-19 infection and were at a high risk of avoiding testing or treatment of a COVID-19  
69 infection due to the fear of mistreatment or discrimination. Access to transgender health  
70 care services was restricted due to the COVID-19 pandemic for 50% of the participants. Male  
71 sex assigned at birth and a lower monthly income were significant predictors for the

72 experience of restrictions to health care. 35.0% of the participants reported at least one  
73 mental health conditions. Every third participant had suicidal thoughts, and 3.2% have  
74 attempted suicide since the beginning of the COVID-19 pandemic. A limitation of the study is  
75 that we did not analyze data from low-income countries and access to the internet was  
76 necessary to participate.

## 77 **Conclusions**

78 Transgender people are assumed to suffer under the severity of the pandemic even more  
79 than the general population due to the intersections between their status as a vulnerable  
80 social group, their high amount of medical risk factors, and their need for ongoing medical  
81 treatment. The COVID-19 pandemic can potentiate these vulnerabilities, add new challenges  
82 for transgender individuals, and, therefore, can lead to devastating consequences, like  
83 severe physical or mental health issues, self-harming behaviour, and suicidality.

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

## 99 **Introduction**

100 Transgender people experience their gender as incongruent with the sex assigned at birth.  
101 They might identify as a binary gender (female, male) or outside of the gender binary.  
102 People who are non-binary might experience their gender as moving between male and  
103 female (e.g., genderfluid) or as situated beyond the gender binary (e.g., genderqueer). Some  
104 reject the concept of sex and gender at all, either on a personal, or a general level (e.g.,  
105 agender). Transgender health care primarily focusses on medical measures to support the  
106 person's transition to live their gender both physically and socially. This may include  
107 hormone therapy, gender-affirming surgery, and a variety of additional interventions (e.g.,  
108 voice and communication therapy, hair removal)[1]. For treatment-seeking transgender  
109 people these interventions positively affect mental health and quality of life, and are thus  
110 considered state-of-the-art treatments [2-5]. However, not all transgender people want to  
111 undergo any of these types of care, or might have access to it [6, 7].  
112 Up to now, transgender people have been considered to be a vulnerable social group, many  
113 of whom have experienced discrimination and marginalization by society, and health care  
114 systems in particular [4, 8]. Access to transgender health care is often restricted due to legal  
115 requirements, financial barriers, and 'gatekeeping' health care providers in countries all over  
116 the world [9, 10]. These elements can lead to a negative impact on transgender individual's  
117 health and quality of life [4].  
118 During to the COVID-19 pandemic access to medical care was, and in some areas globally still  
119 is, restricted for nearly all non-acute medical conditions. State health care, as well as private  
120 practice, were mainly focusing on COVID-19. Since transgender individuals often need access  
121 to medical treatments such as hormone therapy [1], these restrictions are likely to have  
122 increased psychological distress. Due to both their status as a vulnerable social group and

123 their need for transition-related treatments [4, 8], this impact may be particularly severe for  
124 transgender people [11].

125 Even though some authors have already addressed the impact of the COVID-19 pandemic on  
126 transgender people, there remains a dearth of evidence. Perez-Brumer and Silva-Santisteban  
127 [12] discussed the disparities transgender people face in Peru due to binary-based policies as  
128 a response to the COVID-19 pandemic (only women or men are allowed to leave their homes  
129 on certain weekdays) and how this increasing discrimination impacts physical and mental  
130 health. Van der Miesen and colleagues [13] summarized the intersections between health  
131 care, human rights, and socioeconomic stress for transgender individuals during the COVID-  
132 19 pandemic. They state the need for a joint strategy of policy makers, transgender  
133 advocates, health care providers, and governments. Wang and colleagues [11] refer to the  
134 barriers of care for transgender people in times of COVID-19 in light of evidence from their  
135 clinic in Beijing, China. The restricted access to hormone treatment was associated with high  
136 levels of depression and anxiety due to the challenge of continuing presenting and socially  
137 living as their sex assigned at birth. All the authors state the need for collaborative strategies  
138 between relevant stakeholders (e.g., governments, health care providers, advocacy groups)  
139 to actively consider the difficulties faced by the transgender population during the COVID-19  
140 pandemic and the need for high-quality evidence to base strategies upon [11-13].

141 Therefore, as the first of its kind, the current study systematically investigates the impact of  
142 the COVID-19 pandemic on the health and health care of transgender individuals. As an ad  
143 hoc collaboration between researchers, community members and clinicians from several  
144 countries, it aims to generate empirical evidence on the situation of transgender individuals  
145 in times of COVID-19 and, therefore, help to develop and implement measures addressing  
146 the obstacles that affect transgender individuals during the pandemic.

147

## 148 **Methods**

### 149 **Study design**

150 The TransCareCovid-19 survey ([www.transcarecovid-19.com](http://www.transcarecovid-19.com)), is a web-based survey  
151 designed to investigate the effects of the COVID-19 pandemic on health care for transgender  
152 individuals. This cross-sectional study was developed by XX, YY, and ZZ in cooperation with  
153 local health care providers and community members. Several members of the research  
154 group are transgender. Additional consultation was sought in the construction of the survey  
155 by peer and professional organisations.

156 The survey was first developed in German and, in cooperation with 23 community  
157 organisations (for details see [www.transcarecovid-19.com](http://www.transcarecovid-19.com)), translated into 27 languages  
158 (Arabic, Azerbaijani, Armenian, Bulgarian, Chinese, Croatian, Dutch, English, Farsi, French,  
159 Georgian, German, Hungarian, Italian, Kazakh, Kyrgyz, Macedonian, Polish, Portuguese,  
160 Romanian, Russian, Serbian, Spanish, Swedish, Tajik, Turkish, Ukrainian).

161 The study followed strict ethical guidelines and received ethical approval from both the Local  
162 Psychological Ethics Committee at the University Medical Center MM-NN (No.: LPEK-0130,  
163 date: 01/04/2020), as well as from PP University Hospital (BC-07607, date: 15/04/2020). All  
164 respondents provided informed consent.

### 165 **Participants**

166 To recognize the heterogeneity of the transgender population, the survey was open to  
167 anyone who identifies, experiences, and/or describes themselves, as transgender and were  
168 at least 16 years of age. Participants were recruited via postings on LGBTIQ-related social  
169 media channels, mailing lists of support groups and LGBTIQ-related associations, and  
170 through snowball sampling.

171 **Data collection**

172 The data collection started in May 2020 and is still ongoing. The participant recruitment was  
173 supported by several scientific and community organisation (for details see  
174 [www.transcarecovid-19.com](http://www.transcarecovid-19.com)). The present sample is based on the data collected until  
175 August 9, 2020. We choose this date as the COVID-19 pandemic was slowing down in most  
176 countries all over the world and our data allowed us to give a comprehensive overview on  
177 how the first wave of COVID-19 affected transgender people. This paper consists of analyses  
178 of data from high-income and upper middle-income economies according to the World Bank  
179 country classification[14] only, as participant recruitment for lower middle-income and low-  
180 income economies started later.

181 **Variables**

182 The TransCareCovid-19 survey collects demographical data regarding age, education,  
183 occupational status, country of residence, place of residence, residence status, living  
184 situation, financial income, relationship, minority status (person of colour, religious minority,  
185 sexual minority, gender minority, minority due to disability status, another minority), sex  
186 assigned at birth, and gender. The participants' country of residence was classified by the  
187 current World Bank country classification by income level [14]. Upper middle-income  
188 economies are defined as having a gross national income (GNI) per capita of \$4,046 –  
189 \$12,535. A country with a GNI per capita of greater than \$12,535 is considered a high-  
190 income economy. Physical health problems were assessed using items based on established  
191 studies[15, 16] and free-text responses. COVID-19 symptoms, contact history, satisfaction  
192 with information, knowledge, and concerns about COVID-19, were assessed following Wang  
193 and colleagues using 4-point Likert scales (1-highest value, 4-lowest value) [17]. We added  
194 additional items related to transgender-specific discrimination and avoidance of health care

195 based on former studies [16]. Finally, data regarding transition-related health care such as  
196 medical procedures which the respondent has undergone, and the influence of the COVID-  
197 19 pandemic on access to transgender health care and health-related supplies (e.g., chest  
198 binders), were assessed based on an established protocol [18]. Depending on the procedures  
199 which the respondent had undergone, participants were specifically asked about the  
200 influence of the COVID-19 pandemic on single treatments. For example, only participants  
201 who already used hormones were asked if access to their medication was restricted. Fears  
202 about future restrictions on treatment were investigated if participants had already sought  
203 or planned the treatment.

204 Due to the method of participant recruitment, access to a web-enabled device, social media  
205 activity, and technical affinity need to be considered as potential biases. By encouraging  
206 participants to promote the survey with their peers we tried to address the issue of lacking  
207 social media activity. Unfortunately, we were not able to provide a paper-pencil version of  
208 the survey due to the wide range of the study and a lack of financial and human resources.

### 209 **Statistical analysis**

210 Continuous data are presented as mean (SD). Categorical data are presented as n (%).  
211 Missing data were deleted pairwise. To identify factors associated with the experience of  
212 restrictions to transgender health care, we conducted a multivariate logistic regression  
213 analysis. Experiencing restrictions in at least one domain (hormone treatment, hair removal  
214 treatment, surgery, surgical aftercare) was included as depended variable (yes, no). We  
215 entered the covariates in two blocks. Block 1 included age, education (no formal education,  
216 primary, secondary, tertiary education), relationship (yes, no), minority status (person of  
217 colour, religious minority, sexual minority, gender minority), disability (yes, no), sex assigned  
218 at birth (female, male), and gender (binary, non-binary). This block was labelled

219 Demographic Characteristics. Block 2 included the following aspects of the social  
220 environment: Countries' GNI per capita (upper middle-income economy, high- income  
221 economy), residence status (yes, no), population of place of residence (urban, rural), ability  
222 to make ends meet with monthly income (very easily, easily, fairly easily, with some  
223 difficulty, with difficulty, with great difficulty), and health insurance (yes, no). This block was  
224 labelled Social Environment. Cox and Snell's R<sup>2</sup> and Nagelkerke's R<sup>2</sup> are reported as  
225 coefficients of determination. To check for violations of assumptions for logistic regression  
226 such as independence of errors, incomplete information from the predictors, diagnostics  
227 were conducted on all relevant variables. Collinearity diagnostics did not reveal significant  
228 multicollinearity concerns for any of the variables in the model. A p value of <.05 was  
229 considered to be statistically significant. SPSS 24.0 was used for all statistical analyses.

230

## 231 **Results**

232 Between May 1, 2020, and August 9, 2020, 7905 potential participants accessed the survey.  
233 597 participants did not give informed consent and thus were not able to access the survey.  
234 Another 593 participants gave informed consent but did not answer any further questions.  
235 From the remaining 6715 participants, 1223 individuals were excluded from the analyses  
236 because they did not respond to at least 50% of the survey. For the present analysis, 225  
237 participants from low-income and lower middle-income economies were not included. The  
238 final dataset consisted of 5267 participants.  
239 On average, the present sample is of early middle age (30.70 years  $\pm$  12.06), highly educated  
240 (60.7% tertiary education), mostly single (48.7%), and living in an urban environment  
241 (79.9%). 57.3% were assigned female at birth. 74.0% identified as binary [trans] man or  
242 [trans] woman, whereas 21.5% identified as a non-binary gender.

243 Basic and transgender-related demographics are presented in Table 1. Table 2 and Fig 1  
 244 show the current country of residence of the participants.[14] Most participants lived in  
 245 European countries. Fig 2 gives an overview of the physical health problems of the  
 246 participants. 2768 (52.6%) reported a least one acute or chronic condition. 525 (10.0%)  
 247 reported that these conditions resulted in severe limitations in daily activities, 1674 (31.8%)  
 248 reported limitations to some extent. 509 (9.7%) had no limitations due to their chronic  
 249 condition. 1009 (19.2%) of the participants were smokers. 327 (6.2%) used to smoke but had  
 250 recently stopped. 3035 (73.6%) had at least once in their life seriously considered suicide,  
 251 1827 (35.1%) had had suicidal thoughts since the beginning of the COVID-19 pandemic. 1797  
 252 (34.5%) had had at least once suicide attempt, 168 (3.2%) have attempted suicide since the  
 253 beginning of the COVID-19 pandemic.

254

255 **Table 1** Demographics and social situation

	N (%)
Total N°	5267 (100.00%)
Age	
Years (Mean [SD])	30.70 (12.06)
Range	15.00 - 81.00
Education	
No formal education	42 (0.8%)
Primary education	354 (6.7%)
Secondary education	1019 (19.3%)
Tertiary education: vocational education and training	608 (11.5%)
Tertiary education: college/university	2589 (49.2%)
Other	302 (5.7%)
I cannot or do not wish to answer the question	87 (1.7%)
Missing	266 (5.1%)
Relationship	
Single	2563 (48.7%)
Married, living together	424 (8.1%)
Married, but living separately	83 (1.6%)
Registered relationship, living together	82 (1.6%)
Registered relationship, but living separately	37 (0.7%)
Non-registered relationship, living together	669 (12.7%)

Non-registered relationship, but living separately	675 (12.8%)
In more than one relationship	199 (3.8%)
Widowed	14 (0.3%)
Other	198 (3.6%)
I cannot or do not wish to answer the question	60 (1.1%)
Missing	266 (5.1%)
Occupational status <sup>a</sup>	
Student	1780 (33.8%)
Vocational training	226 (4.3%)
Unskilled worker	163 (3.1%)
Employee	1635 (31.0%)
Civil servant	185 (3.5%)
Self-employed	447 (8.5%)
Informal employment	119 (2.3%)
Unemployed	812 (15.4%)
Retired	112 (2.1%)
Unable to work	422 (8.0%)
Other	400 (7.6%)
I cannot or do not wish to answer the question	52 (1.0%)
Minority status <sup>a</sup>	
Person of color	528 (10.5%)
Religious minority	908 (17.3%)
Sexual minority	4414 (83.8%)
Gender minority	4842 (91.9%)
Minority due to disability status	1438 (27.3%)
Another minority	1013 (19.3%)
Gender	
(Trans) man	2141 (40.6%)
(Trans) woman	1761 (33.4%)
Cross-dresser	46 (0.9%)
Non-binary/genderqueer /agender/ polygender/genderfluid	1131 (21.5%)
I don't know, I don't have a preference	144 (2.7%)
Missing	44 (0.8%)
Living according to gender	
Never	370 (7.0%)
Occasionally	998 (18.9%)
Almost always	1249 (23.7%)
Always	2619 (49.7%)
Missing	31 (0.6%)
Sex assigned at birth	
Female	3018 (57.3%)
Male	2194 (41.7%)

	Missing	55 (1.0%)
Place of residence		
	City or the suburbs or outskirts of a city, or town	4210 (79.9%)
	A country village, farm, or home in the countryside	1043 (19.8%)
	Missing	14 (0.3%)
Change of living situation due to COVID-19		
	Missing	10 (0.2%)
Other people living in household		
	Missing	0 (0.0%)
Garden, balcony, other outdoor space		
	Missing	20 (0.4%)
Distress due to current living situation		
	Missing	13 (0.2%)
Making ends meet with the available monthly income		
	Very easily	746 (14.2%)
	Easily	990 (18.8%)
	Fairly easily	1380 (26.2%)
	With some difficulty	1042 (19.8%)
	With difficulty	507 (9.6%)
	With great difficulty	390 (7.4%)
	I don't want to say	78 (1.5%)
	I don't know	121 (2.3%)
	Missing	13 (0.2%)

256 <sup>a</sup> Multiple answers were possible

257

258 **Table 2** Countries

Upper middle-income countries	762 (14.5%)
Argentina	6 (0.1%)
Armenia	34 (0.6%)
Azerbaijan	19 (0.3%)
Belarus	3 (0.1%)
Bosnia and Herzegovina	3 (0.1%)
Botswana	3 (0.1%)
Brazil	36 (0.7%)
Bulgaria	14 (0.3%)
China	150 (2.7%)
Georgia	27 (0.5%)
Indonesia	2 (0.1%)
Iran	1 (0.1%)

Iraq	1 (0.1%)
Kazakhstan	30 (0.5%)
Lebanon	6 (0.1%)
Malaysia	2 (0.1%)
Mexico	2 (0.1%)
Montenegro	16 (0.3%)
Namibia	4 (0.1%)
North Macedonia	17 (0.3%)
Russia	61 (1.1%)
Serbia	69 (1.3%)
South Africa	75 (1.4%)
Turkey	181 (3.3%)
High-income countries	4505 (85.5%)
Australia	109 (2.0%)
Austria	94 (1.7%)
Barbados	1 (0.1%)
Belgium	229 (4.2%)
Canada	128 (2.3%)
Chile	1 (0.1%)
Croatia	30 (0.5%)
Czech Republic	33 (0.6%)
Denmark	17 (0.3%)
Finland	62 (1.1%)
France	66 (1.2%)
Germany	1311 (23.9%)
Greece	6 (0.1%)
Hungary	74 (1.3%)
Iceland	2 (0.1%)
Ireland	8 (0.1%)
Israel	4 (0.1%)
Italy	48 (0.9%)
Japan	3 (0.1%)
Latvia	1 (0.1%)
Liechtenstein	1 (0.1%)
Luxembourg	2 (0.1%)
Malta	7 (0.1%)
Netherlands	175 (3.2%)
New Zealand	37 (0.7%)
Norway	33 (0.6%)
Poland	296 (5.4%)
Portugal	14 (0.3%)
Republic of Korea	1 (0.1%)
Romania	1 (0.1%)
Seychelles	2 (0.1%)
Slovakia	3 (0.1%)
Slovenia	6 (0.1%)
Spain	136 (2.5%)

Sweden	328 (6.0%)
Switzerland	303 (5.5%)
United Kingdom	563 (10.3%)
United States	366 (6.7%)
Taiwan	1 (0.1%)
Missing	38 (0.7%)

259

260 **Fig 1** Participants current country of residence

261

262 **Fig 2** Acute and chronic conditions associated with a risk of a severe course of a COVID-19  
263 infection

264

265 Table 3 gives an overview on COVID-19-related topics. Participants were quite satisfied with  
266 the information they received on the COVID-19 pandemic (M: 2.13 ± 0.8) and had high  
267 confidence in medical personnel to diagnose COVID-19 (M: 2.01 ± 0.8). Participants assumed  
268 it as not very likely to be diagnosed with COVID-19 (M: 2.90 ± 0.9) and as highly likely to  
269 survive a COVID-19 infection (M: 1.63 ± 0.8). They were concerned that members of their  
270 families or close friends will contract COVID-19 (M: 2.09 ± 0.9).

271

272 **Table 3** COVID-19 health care, avoidance, and knowledge

COVID-19 health care	
Tested for COVID-19 within the last 14 days	130 (2.5%)
In quarantine within the last 14 days	1481 (28.1%)
Diagnosed with COVID-19	20 (0.4%)
Recovered from COVID-19	14 (0.3%)
Direct contact with a person diagnosed with COVID-19	109 (2.1%)
Indirect contact with a person diagnosed with COVID-19	245 (4.7%)
Contact with a person suspected to have COVID-19	818 (15.5%)
COVID-19 health care avoidance	
Avoided COVID-19 testing because of fear of mistreatment	295 (5.6%)
Avoided COVID-19 testing because of fear of discrimination	356 (6.8%)
Will avoid COVID-19 testing because of fear of mistreatment	761 (14.4%)
Will avoid COVID-19 testing because of fear of discrimination	888 (16.9%)
COVID-19 knowledge	

Transmission via droplet infection	5040 (95.7%)
Increasing number of infections worldwide	5091 (96.7%)
Increasing number of deaths worldwide	5067 (96.2%)
Increasing number of survivals worldwide	4592 (87.2%)

273

274

275 Table 4 summarises the influence of the COVID-19 pandemic on transgender health care. Of

276 the 4699 participants that had undergone transition-related treatment or planned to do so,

277 2875 (61.2%) feared access restrictions to transgender health care in the future due to the

278 COVID-19 pandemic. Of the 3463 participants that had already undergone transition-related

279 treatment, 1706 (49.3%) experienced restrictions in access to transgender health care

280 services. A multivariate logistic regression analysis revealed that the sex assigned at birth

281 and the adequacy of the monthly income predicted the experience of restrictions to

282 transgender health care significantly. Participants assigned male at birth (OR: 2.239) and

283 individuals with a lower income (OR: 1.102) were at greater risk of experiencing restrictions

284 to transgender health care procedures (Table 5).

285

286 **Table 4** Restrictions regarding transgender health care due to the COVID-19 pandemic

	N (% <sup>a</sup> )
Accessed at least one transgender health care procedure	3463 (65.7%)
Experienced restrictions in access to transgender health care	1706 (49.3%)
Accessed or planned at least one transgender-related treatment procedure	4699 (89.2%)
Fear restrictions to transgender health care in the future	2875 (61.2%)
Access to hormones currently restricted	676 (21.8%)
I cannot get a prescription	162 (24.0%)
I cannot get an appointment with my hormone prescriber	249 (36.8%)
A scheduled appointment was canceled without replacement	110 (16.3%)
An appointment has been postponed	81 (12.0%)
I am afraid to go to a medical provider or a hospital	189 (28.0%)
My hormones cannot be supplied or can only be supplied at a lower dosage than has been prescribed to me	177 (26.2%)
Other	224 (33.1%)

Fear that access to hormones will be affected in the future	2316 (44.0%)
Access to hair removal treatment currently restricted	665 (63.4%)
Fear that access to hair removal treatment will be affected in the future	776 (44.1%)
Surgery cancelled or postponed	
Yes	454 (15.6%)
Not yet, but I expect it will	568 (19.5%)
Problems with aftercare for recent surgery	344 (56.4%)
I cannot get an appointment for aftercare	45 (13.1%)
A scheduled appointment was canceled without replacement	70 (20.3%)
An appointment has been postponed	84 (24.4%)
Complications (e.g., secondary bleeding) have not been treated	22 (6.4%)
I am afraid to go to a doctor or a hospital	41 (11.9%)
Other	82 (23.8%)
Fear that surgical aftercare will be affected in the future	316 (21.9%)
Access restricted to	
medical material necessary after surgery (e.g., vaginal dilators)	160 (3.0%)
other material (e.g., binders, packing material)	651 (12.4%)
non-medical supplies (e.g., wigs, make-up)	860 (16.3%)
Access to counselling services (e.g., peer counselling) limited	2285 (43.4%)
Alternative options for accessing counselling services	1271 (47.9%)
Undergoing mental health care (e.g., for depression)	2055 (39.0%)
Access to mental health care limited	1271 (61.9%)
Fear that access to mental health care will be affected in the future	1035 (50.4%)
Member of a support group	1543 (28.5%)
Access to support groups limited	1067 (69.2%)

287 <sup>a</sup> Percentages refer to the number of participants who assessed a certain transgender health  
 288 service, not to the total sample

289

290 **Table 5** Multiple regression analysis regarding the experience of restrictions to transgender  
 291 health care

	b ± SE	CI	p	OR (95% CI)
Demographics				
Age	0.000 ± 0.003	-0.007 - 0.006	0.899	1.000 (0.993, 1.006)
Education	-0.013 ± 0.067	-0.148 - 0.119	0.850	0.987 (0.869, 1.121)

Relationship	0.033 ± 0.079	-0.123 - 0.201	0.677	1.033 (0.886, 1.205)
POC	0.158 ± 0.145	-0.129 - 0.436	0.269	1.171 (0.885, 1.550)
Religious minority	-0.083 ± 0.118	-0.320 - 0.144	0.466	0.920 (0.742, 1.142)
Sexual minority	0.000 ± 0.116	-0.220 - 0.236	0.997	1.215 (0.891, 1.657)
Gender minority	0.194 ± 0.157	-0.104 - 0.490	0.217	1.081 (0.891, 1.657)
Disability	0.077 ± 0.095	-0.097 - 0.276	0.388	0.380 (0.903, 1.657)
Sex assigned at birth	0.967 ± 0.082	0.809 - 1.136	0.001	2.239 (2.239, 3.092)
Non-binary gender	-0.034 ± 0.119	-0.262 - 0.213	0.767	0.966 (0.769, 1.214)
Social Environment				
Countries GNI per capita	-0.167 ± 0.115	-0.392 - 0.056	0.153	0.846 (0.677, 1.057)
Residence status	-0.312 ± 0.254	-0.845 - 0.182	0.212	0.732 (0.449, 1.191)
Population place of residence	0.106 ± 0.102	-0.092 - 0.320	0.292	1.111 (0.913, 1.354)
Monthly income	0.097 ± 0.028	0.045 - 0.150	0.003	1.102 (1.043, 1.164)
Health insurance	0.093 ± 0.175	-0.255 - 0.422	0.600	1.098 (0.792, 1.521)
Constant	0.754 ± 0.554	-0.283 - 1.840	0.172	0.808

292  $R^2$  0.063 (Cox & Snell), 0.084 (Nagelkerke). Model  $\chi^2$  (15) = 186.693, p=0.000

293

## 294 Discussion

295 As the first of its kind, the current study provides empirical insights into how the COVID-19  
 296 pandemic affects the health care of transgender people in higher middle-income and high-  
 297 income countries. Over 50% of our participants had risk factors for a severe course of a  
 298 COVID-19 infection and were at a high risk of avoiding testing or treatment of a potential  
 299 COVID-19 infection due to fear of mistreatment and/or discrimination. Transgender health  
 300 care was highly affected by the COVID-19 pandemic, with almost half of participants  
 301 experiencing some sort of restricted access to health care. Restricted access to transgender  
 302 health care applied rather universally to all transgender individuals, with a male sex assigned  
 303 at birth and a lower monthly income as the only significant predictors.

304 We found, that over 50% of transgender individuals have risk factors for a severe course of a  
 305 COVID-19 infection (i.e., pre-existing medical conditions, being a smoker).[19-22] Compared  
 306 with that, 23.5% of the working population in the EU and one-third of the European general  
 307 population over 15 suffer from chronic conditions [23]. Similar numbers were found for  
 308 other OECD countries [24]. Only in the US is the prevalence of chronic conditions between  
 309 the transgender and the general population approximately equal, with 6 out of 10 adults

310 having a chronic condition [25]. Additionally, our participants were likely to avoid COVID-19  
311 testing or care because of fears of discrimination or mistreatment. This was true even  
312 though they were aware of the potential severity of COVID-19. This avoidance of care could  
313 even worsen their risk for serious consequences of COVID-19.

314 We found that access to all transgender health care interventions was restricted due to the  
315 COVID-19 pandemic. This could be especially important for those who access ongoing  
316 treatments such as hormone therapy [3]. Hormone therapy is considered one of the most  
317 important treatment options for many transgender individuals and is highly associated with  
318 better mental health and quality of life [26]. An interruption of a hormone therapy is not  
319 associated with physical risks when gonadectomy was not performed. However, mental  
320 health risks must be considered. Stopping hormone treatment is often associated with a  
321 return of some features related to the sex assigned at birth (e.g., the return of  
322 menstruation). Moreover, mood swings and symptoms of depression and anxiety can occur  
323 [2, 3, 27]. There is a risk of psychological distress for the twenty percent of our sample  
324 whose hormones have been, or still are, restricted due to the pandemic. This association has  
325 also been reported by Wang and colleagues in their clinic in Beijing, China [11]. The same  
326 may well be true for hair removal treatments. While hair removal might not have the same  
327 value as hormone treatment, it is often performed as a supportive measure as hormone  
328 treatment alone could be insufficient to eliminate hair growth [27]. As a population,  
329 transgender individuals are already experiencing poor mental health, decreased quality of  
330 life, and are at high risk of discrimination and harassment [4, 8]; consequently, the  
331 restrictions in access to health care may affect transgender people to a greater extent than  
332 the general population. This higher vulnerability might also intersect with other minority  
333 statuses, such as being a person of colour.

334 All these transgender-specific issues caused by the COVID-19 pandemic need to be  
335 addressed by both structural changes as well as counselling services (e.g., peer counselling)  
336 and mental health care professionals. However, due to the COVID-19 pandemic, access to  
337 these measures is limited, too. For 43.4% of the participants who assessed counselling  
338 services, the access to those was restricted. 61.9% of those who undergo mental health care  
339 (e.g., for a pre-existing affective disorder) experienced access restrictions. Only half of the  
340 participants had alternative options for accessing counselling services (e.g., online  
341 consultations). Additionally, even access to low-threshold services, like support groups, was  
342 limited for two thirds of their members. In light of the available data, the COVID-19  
343 pandemic and its associated restrictions, combined with the systemic inequalities  
344 transgender people face in almost every country in the world, appears to have had a  
345 significant impact on the (mental) health of transgender people. Tragically, our study found  
346 that more than one third of our sample had had suicidal thoughts and 3.2% had attempted  
347 suicide since the beginning of the pandemic. And even though no causal conclusions can be  
348 drawn based on our cross-sectional study, it seems reasonable to assume that many of these  
349 suicidal attempts are linked to the situation caused by the COVID-19 pandemic. Indeed, at  
350 the least this association ought to be a warning sign that transgender people might be  
351 disproportionately affected by COVID-19.

352 Some treatment options for transgender people such as genital surgeries [1] have been  
353 highly restricted due to the COVID-19 pandemic, too. At the time of the data analysis,  
354 approximately 15.6% of surgeries were already cancelled and another 19.5% of the  
355 participants expected their surgery to be cancelled. Additionally, aftercare for recent surgery  
356 was also restricted. As genital surgery is considered an important treatment option to  
357 increase quality of life and reduce psychological distress in transgender people [2, 28], a

358 postponement of these procedures can negatively impact a person's well-being. Especially  
359 regarding surgical aftercare, restrictions could lead to serious health concerns like wound  
360 infections or disorders of wound healing [2]. Moreover, due to insecurities caused by the  
361 postponement of surgery, mental health problems could occur which should be addressed  
362 by counselling services or mental health professionals when possible. However, as the access  
363 to these services is restricted too, problems associated with postponed surgeries might not  
364 be addressed sufficiently and could intersect with already existing distress such as  
365 restrictions to accessing hormone treatment.

366 All potential distress caused by restrictions to transgender health care might be further  
367 affected by social and socio-economic circumstances, as already reported by Perez-Brumer  
368 and Silva-Santisteban [12]. We found that one third of our participants had difficulties  
369 making ends meet with their available monthly income and another third experienced  
370 distress due to their current living situation. However, using regression analysis, we only  
371 found a male sex assigned at birth and a lower monthly income to be significant predictors  
372 for the experience of restrictions to transgender health care. The significant association to a  
373 male sex assigned at birth could be due to a greater stigma towards transgender people  
374 assigned male at birth [29]. The association between the monthly income and a higher risk  
375 of restrictions to transgender health care with an OR of 1.102 could be considered weak.  
376 Therefore, it seems that the COVID-19 pandemic hits the transgender population in higher-  
377 middle-income and high-income countries in its entirety and that there aren't any major  
378 protective social factors.

379 The strength of our study is that it includes a high number of participants from several  
380 countries all over the world. This is important as, with a number of 6.8 to 355 per 100,000,  
381 transgender people are only a small group within the general population [30]. The results

382 are therefore likely to be applicable to other upper middle-income and high-income  
383 countries with similar health systems. Moreover, the study was developed and conducted by  
384 transgender researchers in close cooperation with community organisations. Therefore, we  
385 intentionally took power differences between researchers and study subjects into account  
386 and tried to ensure tangible outcomes for the community.

387 We consider the type of data collection a potential limitation of our study due to access to  
388 the internet being a necessity. This could have excluded participants with low income or  
389 without experience with digital technology. However, our sample was comparable to  
390 previous studies, in terms of gender or education, for example [7, 18]. As there is still a  
391 dynamic COVID-19 situation, with increasing and decreasing numbers of infections and  
392 changing national measures to address these, this research also did not explore international  
393 comparisons. In countries where COVID-19 has been more effectively suppressed the  
394 impacts of COVID-19 could, therefore, be lower. Moreover, we only analysed data from  
395 higher middle-income and high-income countries, which is why the results cannot be  
396 generalized to countries with lower GNI per capita. However, as participant recruitment in  
397 lower middle-income countries and low-income countries appeared to be difficult (but is still  
398 ongoing) the clear need for evidence of how COVID-19 affects transgender people led us to  
399 focus on the present data. We currently strive to provide data from lower middle-income  
400 countries and low-income countries as soon as possible.

401 In sum, it appears that the COVID-19 pandemic has an extraordinary impact on the  
402 transgender population in higher middle-income and high-income countries, and that  
403 transgender people might suffer under the severity of the pandemic even more than the  
404 general population. This is due to the intersections between their status as a vulnerable  
405 social group, their high amount of medical risk factors, and their need for ongoing medical

406 treatment. The COVID-19 pandemic can potentiate these vulnerabilities, add new challenges  
407 for transgender people, and can therefore lead to devastating consequences such as severe  
408 physical or mental health issues, self-harming behaviour, and even suicidality.

409

#### 410 **Acknowledgements**

411 A worldwide survey needs a lot of helping hands. Annette Güldenring (Heide, Germany and  
412 Bundesverband Trans\*) as well as Petra Weitzel and Lena Balk (both dgti, Germany) actively  
413 supported us in the development of the questionnaire in the original version in German.  
414 Julia Kata from Trans-Fuzja was also very helpful in distributing the questionnaire in Poland.  
415 The data from Mainland China would not have been possible without the help of Eddy Xu  
416 and the team of The Trans Well-Being Project. For the USA, Asa Radix, MD, and Ayden  
417 Scheim, PhD, were also very helpful.

418

#### 419 **Funding**

420 The author(s) received no specific funding for this work.

421

#### 422 **Contributors**

423 XX, YY, and ZZ conceived the study. All authors reviewed the study concerning country-specific  
424 issues. All authors contributed to participant recruitment and data collection. XX, YY, and ZZ  
425 managed the data and did the statistical analysis. All authors collaborated in interpretation of  
426 the results and drafting and revision of the manuscript.

427

#### 428 **Declaration of Interests**

429 All authors declare no competing interests.

#### 430 **Data sharing**

431 We will consider sharing de-identified, individual participant-level data that underlie the results  
432 reported in this Article on receipt of a request detailing the study hypothesis and statistical  
433 analysis plan. All requests should be sent to the corresponding author. The corresponding author  
434 and lead investigators of this study will discuss all requests and make decisions about whether  
435 data sharing is appropriate based on the scientific rigour of the proposal. All applicants will be  
436 asked to sign a data access agreement.

437


## 438 **References**

- 439 1. Safer JD, Tangpricha V. Care of transgender persons. *N Engl J Med*.  
440 2019;381(25):2451-60.
- 441 2. Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al.  
442 Standards of care for the health of transsexual, transgender, and gender-  
443 nonconforming people, version 7. *Int J Transgend*. 2012;13(4):165-232.
- 444 3. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et  
445 al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an  
446 endocrine society clinical practice guideline. *J Clin Endocrinol Metab*.  
447 2017;102(11):3869-903.
- 448 4. Reisner SL, Poteat T, Keatley J, Cabral M, Mothopeng T, Dunham E, et al. Global  
449 health burden and needs of transgender populations: a review. *Lancet*.  
450 2016;388(10042):412-36.
- 451 5. Dhejne C, Van Vlerken R, Heylens G, Arcelus J. Mental health and gender dysphoria: A  
452 review of the literature. *Int Rev Psychiatry*. 2016;28(1):44-57.
- 453 6. Motmans J, Nieder TO, Bouman WP. Transforming the paradigm of nonbinary  
454 transgender health: A field in transition. Taylor & Francis; 2019.


- 455 7. Koehler A, Eysse J, Nieder TO. Genders and individual treatment progress in (non-)  
456 binary trans individuals. *J Sex Med.* 2018;15(1):102-13.
- 457 8. Koch JM, McLachlan Ct, Victor CJ, Westcott J, Yager C. The cost of being transgender:  
458 where socio-economic status, global health care systems, and gender identity  
459 intersect. *Psychol Sex.* 2020;11(1-2):103-19.
- 460 9. Safer JD, Coleman E, Feldman J, Garofalo R, Hembree W, Radix A, et al. Barriers to  
461 health care for transgender individuals. *Curr Opin Endocrinol Diabetes Obes.*  
462 2016;23(2):168.
- 463 10. Fontanari AMV, Zanella GI, Feijó M, Churchill S, Lobato MIR, Costa AB. HIV-related  
464 care for transgender people: A systematic review of studies from around the world.  
465 *Soc Sci Med.* 2019;230:280-94.
- 466 11. Wang Y, Pan B, Liu Y, Wilson A, Ou J, Chen R. Health care and mental health  
467 challenges for transgender individuals during the COVID-19 pandemic. *Lancet*  
468 *Diabetes Endocrinol.* 2020. doi: [https://doi.org/10.1016/S2213-8587\(20\)30182-0](https://doi.org/10.1016/S2213-8587(20)30182-0).
- 469 12. Perez-Brumer A, Silva-Santisteban A. COVID-19 policies can perpetuate violence  
470 against transgender communities: insights from Peru. *AIDS Behav.* 2020:1.
- 471 13. van der Miesen AI, Raaijmakers D, van de Grift TC. “You Have to Wait a Little Longer”:  
472 Transgender (Mental) Health at Risk as a Consequence of Deferring Gender-Affirming  
473 Treatments During COVID-19. *Arch Sex Behav.* 2020:1.
- 474 14. Bank W. World Bank Country and Lending Groups 2020. Available from:  
475 <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519>.
- 476 15. Hill BJ, Bouris A, Barnett JT, Walker D. Fit to serve? Exploring mental and physical  
477 health and well-being among transgender active-duty service members and veterans  
478 in the US Military. *Transgend Health.* 2016;1(1):4-11.

- 479 16. Motmans J, Wyverkens E, Defreyne J. Being transgender in Belgium. Ten years later.  
480 Institute for the equality of women and men: Brussels. 2017.
- 481 17. Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, et al. Immediate psychological responses  
482 and associated factors during the initial stage of the 2019 coronavirus disease  
483 (COVID-19) epidemic among the general population in China. *Int J Environ Res Public*  
484 *Health*. 2020;17(5):1729.
- 485 18. Eyssel J, Koehler A, Dekker A, Sehner S, Nieder TO. Needs and concerns of  
486 transgender individuals regarding interdisciplinary transgender healthcare: A non-  
487 clinical online survey. *PLoS One*. 2017;12(8):e0183014.
- 488 19. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence.  
489 *Tob Induc Dis*. 2020;18.
- 490 20. Razzaghi H, Wang Y, Lu H, Marshall KE, Dowling NF, Paz-Bailey G, et al. Estimated  
491 county-level prevalence of selected underlying medical conditions associated with  
492 increased risk for severe covid-19 illness—united states, 2018. *MMWR Surveill*  
493 *Summ*. 2020;69(29):945.
- 494 21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for  
495 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort  
496 study. *Lancet*. 2020.
- 497 22. Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for  
498 COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a  
499 population-based cohort study. *Lancet Diabetes Endocrinol*. 2020.
- 500 23. OECD, Union E. Health at a Glance: Europe 2016.2016.
- 501 24. OECD. Health at a Glance 2019.2019.

- 502 25. Prevention CfDCa. About Chronic Diseases 2020 [cited 2020 10/04]. Available from:  
503 <https://www.cdc.gov/chronicdisease/about/index.htm>.
- 504 26. White Hughto JM, Reisner SL. A systematic review of the effects of hormone therapy  
505 on psychological functioning and quality of life in transgender individuals. *Transgend*  
506 *Health*. 2016;1(1):21-31.
- 507 27. Deutsch MB. Guidelines for the primary and gender-affirming care of transgender  
508 and gender nonbinary people: University of California, San Francisco; 2016.
- 509 28. Murad MH, Elamin MB, Garcia MZ, Mullan RJ, Murad A, Erwin PJ, et al. Hormonal  
510 therapy and sex reassignment: A systematic review and meta-analysis of quality of  
511 life and psychosocial outcomes. *Clin Endocrinol (Oxf)*. 2010;72(2):214-31.
- 512 29. Budge SL, Adelson JL, Howard KA. Anxiety and depression in transgender individuals:  
513 the roles of transition status, loss, social support, and coping. *J Consult Clin Psychol*.  
514 2013;81(3):545.
- 515 30. Collin L, Reisner SL, Tangpricha V, Goodman M. Prevalence of transgender depends  
516 on the “case” definition: a systematic review. *J Sex Med*. 2016;13(4):613-26.  
517



**Fig 1** Participants current country of residence



**Fig 2** Acute and chronic conditions associated with a risk of a severe course of a COVID-19 infection